Information Bias in Electronic Health Records and Administrative Claims Data: A Targeted Review of the Recent Literature.

IF 5.5 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Patrick J Arena, Yezhou Sun, Ashley Jaksa, Yu-Han Kao, Lara Yoon, Ke Meng, Arielle Marks-Anglin, Vladimir Turzhitsky
{"title":"Information Bias in Electronic Health Records and Administrative Claims Data: A Targeted Review of the Recent Literature.","authors":"Patrick J Arena, Yezhou Sun, Ashley Jaksa, Yu-Han Kao, Lara Yoon, Ke Meng, Arielle Marks-Anglin, Vladimir Turzhitsky","doi":"10.1002/cpt.70105","DOIUrl":null,"url":null,"abstract":"<p><p>Randomized clinical trials represent the primary source of evidence for regulatory and health technology assessment (HTA) decision making; however, the integration of real-world evidence (RWE) has increased in recent years. Despite its utility, RWE is often threatened by information bias, and the literature addressing measurement error in RWE remains underdeveloped. To address this gap, we conducted a targeted literature review to identify and synthesize mitigation measures for information bias in RWE generation among studies using electronic health records (EHRs) and administrative claims data. Our review covered articles published between January 2019 and May 2024 and included real-world data (RWD) investigations with a focus on information bias case studies or review articles; to increase the utility of our results, the Food and Drug Administration's guidance on assessing EHRs and medical claims data was also incorporated. Data elements were extracted and categorized to produce a comprehensive information bias mitigation framework. In total, 38 articles and guidance documents were included, primarily focusing on studies conducted in the United States (n = 25) as well as studies using EHR data (n = 31). Findings were synthesized into 15 general recommendations: six targeting study design, four addressing study variables, and five focused on statistical analyses. Prominent themes included validation, data linkage, and quantitative bias analysis. Overall, our findings underscore the diversity and complexity of the information bias in RWD literature. Our resulting framework offers practical recommendations and complements prior work, providing a foundation for future efforts to enhance the validity of RWE in regulatory/HTA decision making.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cpt.70105","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Randomized clinical trials represent the primary source of evidence for regulatory and health technology assessment (HTA) decision making; however, the integration of real-world evidence (RWE) has increased in recent years. Despite its utility, RWE is often threatened by information bias, and the literature addressing measurement error in RWE remains underdeveloped. To address this gap, we conducted a targeted literature review to identify and synthesize mitigation measures for information bias in RWE generation among studies using electronic health records (EHRs) and administrative claims data. Our review covered articles published between January 2019 and May 2024 and included real-world data (RWD) investigations with a focus on information bias case studies or review articles; to increase the utility of our results, the Food and Drug Administration's guidance on assessing EHRs and medical claims data was also incorporated. Data elements were extracted and categorized to produce a comprehensive information bias mitigation framework. In total, 38 articles and guidance documents were included, primarily focusing on studies conducted in the United States (n = 25) as well as studies using EHR data (n = 31). Findings were synthesized into 15 general recommendations: six targeting study design, four addressing study variables, and five focused on statistical analyses. Prominent themes included validation, data linkage, and quantitative bias analysis. Overall, our findings underscore the diversity and complexity of the information bias in RWD literature. Our resulting framework offers practical recommendations and complements prior work, providing a foundation for future efforts to enhance the validity of RWE in regulatory/HTA decision making.

电子健康记录和行政索赔数据中的信息偏差:近期文献的目标回顾。
随机临床试验是监管和卫生技术评估(HTA)决策的主要证据来源;然而,近年来,现实世界证据的整合(RWE)有所增加。尽管RWE很实用,但它经常受到信息偏差的威胁,并且关于RWE测量误差的文献仍然不发达。为了解决这一差距,我们进行了一项有针对性的文献综述,以确定和综合使用电子健康记录(EHRs)和行政索赔数据的研究中RWE产生的信息偏差的缓解措施。我们的综述涵盖了2019年1月至2024年5月之间发表的文章,包括现实世界数据(RWD)调查,重点是信息偏见案例研究或综述文章;为了提高我们的结果的效用,我们还纳入了食品和药物管理局关于评估电子病历和医疗索赔数据的指导。提取数据元素并对其进行分类,以产生一个全面的信息偏差缓解框架。总共纳入了38篇文章和指导文件,主要集中在美国进行的研究(n = 25)以及使用EHR数据的研究(n = 31)。研究结果被综合为15项一般性建议:6项针对研究设计,4项针对研究变量,5项侧重于统计分析。突出的主题包括验证、数据链接和定量偏倚分析。总的来说,我们的研究结果强调了RWD文献中信息偏差的多样性和复杂性。我们的结果框架提供了实用的建议,并补充了之前的工作,为未来努力提高RWE在监管/HTA决策中的有效性奠定了基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
12.70
自引率
7.50%
发文量
290
审稿时长
2 months
期刊介绍: Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original Articles in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信